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(248 of 250 words) 
Background and purpose: We externally validated a previously established 
multivariable normal-tissue complication probability (NTCP) model for Grade 
≥2 acute esophageal toxicity (AET) after intensity-modulated (chemo-
)radiotherapy or volumetric-modulated arc therapy for locally advanced non-55 
small cell lung cancer. 
Materials and Methods: A total of 603 patients from five cohorts (A-E) within 
four different Dutch institutes were included. Using the NTCP model, 
containing predictors concurrent chemoradiotherapy, mean esophageal dose, 
gender and clinical tumor stage, the risk of Grade ≥2 AET was estimated per 60 
patient and model discrimination and (re)calibration performance were 
evaluated.  
Results: Four validation cohorts (A, B, D, E) experienced higher incidence of 
Grade ≥2 AET compared to the training cohort (49.3%-70.2% vs 35.6%; 
borderline significant for one cohort, highly significant for three cohorts). 65 
Cohort C experienced lower Grade ≥2 AET incidence (21.7%, p<0.001). For 
three cohorts (A-C), discriminative performance was similar to the training 
cohort (area under the curve (AUC) 0.81-0.89 vs 0.84). In the two remaining 
cohorts (D-E) the model showed poor discriminative power (AUC 0.64 and 
0.63). Reasonable calibration performance was observed in two cohorts (A-B), 70 
and recalibration further improved performance in all three cohorts with good 
4 
 
discrimination (A-C). Recalibration for the two poorly discriminating cohorts 
(D-E) did not improve performance. 
Conclusions: The NTCP model for AET prediction was successfully validated 
in three out of five patient cohorts (AUC ≥0.80). The model did not perform 75 
well in two cohorts, which included patients receiving substantially different 
treatment. Before applying the model in clinical practice, validation of 
discrimination and (re)calibration performance in a local cohort is 
recommended. 





Acute esophageal toxicity (AET) is frequently observed in locally advanced 
non-small cell lung cancer (LA-NSCLC) patients undergoing (chemo-
)radiotherapy, particularly when patients receive concurrent chemotherapy [1, 85 
2]. Normal-tissue complication probability (NTCP) models can help to estimate 
the risk of moderate or severe AET, which may be of benefit for anticipating 
events of hospitalization or treatment interruptions due to AET [3-7]. These 
multivariable NTCP models may also be used by doctors as a tool to support 
their decision on whether or not to treat at the cost of more AET [8-10]. 90 
Furthermore, in case there is an increased risk of AET, patients may be selected 
that benefit most from other radiotherapy techniques such as proton therapy [11, 
12]. 
The vast majority of the reported NTCP models for AET are based on 3-
dimensional conformal radiotherapy (3D-CRT) techniques. Intensity-modulated 95 
radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT), 
however, produce more conformal dose distributions at the cost of increased 
volumes receiving lower dose [13-16]. These differences may result in a 
different toxicity profile and thus require new NTCP models [17-19]. Therefore, 
the available NTCP models based on 3D-CRT may not be appropriate for AET 100 
risk prediction in patients treated with modern dose delivery techniques. We 
previously reported on an IMRT- and VMAT-based multivariable NTCP model 
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for Grade ≥2 AET [20]. This model was internally validated and the area under 
the receiver operating curve (AUC) was 0.84 (0.82 after correction for 
optimism) indicating good discriminative power of the model. Nonetheless, as 105 
reproducibility (model performance on new samples from the same target 
population), and transportability (model performance on samples from different 
but related populations) of well internally validated prediction models can still 
be poor, external validation is needed to assess ‘generalizability’ of the NTCP 
model to external patient cohorts [21-24]. 110 
In this study, we used five patient cohorts from four different Dutch institutes to 
externally validate the previously reported multivariable NTCP model for Grade 
≥2 AET after IMRT or VMAT for LA-NSCLC (TRIPOD statement Type 4 




Materials and Methods  
Established NTCP model for AET 
The model was developed using a training cohort of 149 LA-NSCLC patients 
who underwent (chemo-)radiotherapy using IMRT or VMAT at the Radboud 
University Medical Center (Nijmegen, The Netherlands) between March 2008 120 
and June 2013. Information on treatment and patient selection has been 
previously described in more detail [20]. In brief, all patients received ≥60 Gy 
(median 66 Gy) in 2 Gy fractions (once daily), with or without (concurrent or 
sequential) chemotherapy (Table 1). The sequential chemotherapy regimen 
typically consisted of 3 (3-weekly) courses of gemcitabine/cisplatin, whereas all 125 
patients undergoing concurrent chemoradiotherapy (CCR) received 2 (3-weekly) 
courses of etoposide/cisplatin. 
AET was scored weekly during treatment by the treating radiation oncologist 
using the Radiation Therapy Oncology Group (RTOG) acute radiation morbidity 
scoring criteria [25]. Toxicity scoring was continued after treatment until acute 130 
toxicity resolved. The AET scores were analysed in relation to clinical risk 
factors and radiation treatment plan derived dose volume histogram (DVH) 
parameters. 
After multivariable logistic regression, with bootstrap sampling for model order 
and predictor selection, the following optimal NTCP model for Grade ≥2 AET 135 








 𝑆(𝑥) = −6.418 + 2.645 ∙ 𝐶𝐶𝑅 + 0.117 ∙ 𝑀𝐸𝐷 + 1.204 ∙ 𝐺𝑒𝑛𝑑𝑒𝑟 + 0.994 ∗ 𝑐𝑇, (2) 
and CCR = concurrent chemoradiotherapy (1 = yes, 0 = no), MED = mean 140 
esophageal dose (preferably first converting physical dose to linear-quadratic 
equivalent dose in 2 Gy fractions with α/β = 10 Gy using MED and its standard 
deviation [8, 26], or esophageal DVH or full dose matrix [27, 28]), gender (1 = 
female, 0 = male) and cT = clinical tumor stage (0 < cT3, 1 ≥ cT3). 
 145 
External validation cohorts 
Five cohorts from four different Dutch institutes were available for validation of 
the abovementioned NTCP model. The patient, tumor and treatment 
characteristics of each cohort are listed in Table 1 and Supplementary Material 
Table S1. Except for cohort D and E, acute toxicity was retrieved retrospectively 150 
for these cohorts from the electronic health records. For all cohorts toxicity was 
scored weekly during radiotherapy and continued after radiotherapy until 
toxicity resolved, maximum AET score was used as outcome for model 
performance evaluation. 
Cohort A (n=47) was also treated in the Department of Radiation Oncology of 155 
the Radboud University Medical Center [20]. This cohort consisted solely of 
stage III NSCLC patients that were treated with (chemo-)radiotherapy using 
VMAT between June 2013 and December 2014. Radiotherapy and 
chemotherapy regimens and AET scoring were similar to those of the training 
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cohort. Cohort B (n=73) consisted of stage III NSCLC patients which received 160 
(chemo-)radiotherapy at ‘Radiotherapiegroep’ (Arnhem, The Netherlands) 
between January 2014 and March 2016 using mostly VMAT. The radiotherapy 
regimen and AET scoring were similar to the training cohort. Sequential 
chemotherapy was platinum based, preferentially cisplatin. Concurrent 
chemotherapy consisted of 2 courses of platinum/etoposide sometimes preceded 165 
by one course of a platinum doublet with either etoposide, or pemetrexed. 
Cohort C consisted of 156 stage I-III NSCLC patients treated with (chemo-
)radiotherapy at The Netherlands Cancer Institute (Amsterdam, The 
Netherlands) between December 1998 and March 2003 using 3D-CRT [29]. For 
27 patients, however, the predictor ‘clinical T-stage’ required in the NTCP-170 
model was not available and therefore 129 patients with complete data were 
included. Varying radiotherapy schedules (total dose 49.5-94.5 Gy, 2.25-2.75 
Gy per fraction) were administered, and sequential and concurrent 
chemotherapy consisted of 2 courses of gemcitabine/cisplatin or daily low-dose 
cisplatin, respectively. The incidence of AET in this cohort has been evaluated 175 
and reported previously; AET was scored using the RTOG scoring criteria [29]. 
Cohort D was also retrieved from The Netherlands Cancer Institute comprising 
172 patients treated between January 2008 and November 2010, and their AET 
was scored using the Common Toxicity Criteria Adverse Effects (CTCAE) v3.0 
[30]. See Table S2 in the Supplementary Material for a comparison between 180 
AET scoring using RTOG, CTCAE v3.0 and v4.0. These patients all underwent 
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concurrent chemoradiotherapy (daily low-dose cisplatin) using IMRT (66 Gy in 
24 fractions) [31]. 
The patients from cohort E (n=398) were treated at MAASTRO Clinic 
(Maastricht, The Netherlands) between April 2006 and October 2013. Of these, 185 
216 patients had missing data, i.e., missing mean esophageal dose (n=201, for 
technical reasons), AET score (n=4; CTCAE v3.0 and v4.0 [32]), chemotherapy 
sequence (n=1) and clinical T-stage (n=10), and thus 182 patients were included. 
Patients received 1-3 courses of induction chemotherapy (gemcitabine or 
cisplatinum) typically followed by concurrent chemotherapy (n=156) or 190 
sequential chemotherapy (n=24) consisting of 2 courses of a platinum-based 
doublet. Two patients received no chemotherapy at all. The majority of patients 
(n=161) received a total radiation dose of 69 Gy in 1.5 Gy fractions twice daily 
up to 45 Gy, followed by 8 to 24 Gy in 2 Gy once daily fractions, depending on 
the dose to the organs at risk (OAR) [33]. Eighteen patients were treated within 195 
the FDG-PET-based international multicenter Phase II dose escalation trial 
“PET-boost” [34]; they received 66 Gy in 24 once daily fractions to the gross 
tumor volume (GTV). In case dose escalation was possible (by increasing the 
fraction dose with equal number of fractions), an integrated boost was delivered 
to the primary tumor as a whole or to the volume of the primary tumor 200 





Differences between the training cohort from which the NTCP model was 
developed and the validation cohorts were tested for statistical significance 205 
using the Mann-Whitney-U or Fisher’s exact test, where appropriate (SPSS 
software, version 22.0; SPSS Inc., Chicago, USA). A p-value of <0.05 was 
considered statistically significant. 
 
Model performance 210 
The risk of Grade ≥2 AET was calculated for each individual patient by 
applying the original NTCP model (Formula 1 and 2). The discriminative power 
of the model for the validation cohorts was assessed by calculating the area 
under the curve (AUC) of the receiver operating characteristic (ROC). The 
criterion for successful external validation was AUC ≥0.80, i.e., no significant 215 
deterioration of model performance with respect to the training cohort (AUC 
0.84, or 0.82 after optimism correction [20]). Furthermore, the discrimination 
slopes were calculated by the absolute difference between the mean predicted 
risk of the groups with and without Grade ≥2 AET. 
Model calibration performance was assessed by calibration plots displaying 220 
grouped observed frequencies versus predicted outcome [35]. A loess smoother 
was plotted, which approximates the y=x identity line in case of good calibration 
[36]. The 95% confidence intervals of the binomially distributed grouped 
frequencies were calculated according to the Wilson interval [37]. Double 
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histograms of predicted probabilities for patients with and without Grade ≥2 225 
AET were also generated for the calibration plots. 
To assess possible miscalibration in the cohorts, the method of logistic 
recalibration was applied [38, 39]. The linear predictors for each patient, i.e., the 
calculated results after inserting patient specific parameters into Formula 2, were 





with updated linear predictor 
 𝑆′(𝑥) = 𝑎 + 𝑏 ∙ 𝑆(𝑥). (4) 
The resulting calibration intercept a (‘calibration-in-the-large’) compares the 
mean of the predicted risks with the mean of the observed risk and gives an 235 
indication whether predictions are systematically under- (a>0) or overestimated 
(a<0). The calibration slope b indicates the level of overfitting (b<1), i.e., the 
predictions are too extreme, or underfitting (b>1), the predictions are too mild. 
Recalibration does neither affect sensitivity nor specificity and thus ROC and 
AUC both remain the same [21, 35]. 240 
The overall performance of the recalibrated models in each cohort was 
additionally assessed by calculation of the scaled Brier score, a quadratic scoring 
rule corrected for dependence on the incidence of the outcome [21]. 
Additionally, Nagelkerke’s R2 was calculated, which is a logarithmic scoring 
rule to express the amount of variance in the dependent variables explained by 245 





Comparison of cohorts 
A comparison of training and validation cohort characteristics for the NTCP 250 
model predictors and AET is listed in Table 1. The incidence of Grade ≥2 AET 
in cohorts A, D and E was (nearly) twice the incidence of Grade ≥2 AET in the 
training cohort (70.2%, 59.3% and 68.1% vs 35.6%, respectively; p<0.001). The 
patients in cohort C experienced lower rates of Grade ≥2 AET compared to the 
training cohort (21.7% vs 35.6%, respectively; p=0.01). Other patient, tumor and 255 




A summary of model performance in the validation cohorts, i.e., overall 260 
performance, discrimination and (re)calibration, is listed in Table 2. 
Unsurprisingly, the best performance, as indicated by the highest value of the 
scaled Brier and Nagelkerke R2, was seen in the training cohort. The overall 
performance was high for cohorts A, B and C, but was poor for cohorts D and E. 
The ROC curves for all cohorts are displayed in Figure 1. High discriminative 265 
performance of similar quality to the training cohort was obtained for cohorts A, 
B and C, as indicated by high AUCs (0.89, 0.81 and 0.84, respectively). Poor 
discrimination of the model was found in cohort D and E (AUC 0.64 and 0.63 
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respectively). This poor discrimination performance is also demonstrated by the 
calculated discrimination slopes (Table 2). 270 
Model calibration performance, without recalibration, can be visually assessed 
from the calibration plots shown in Figure S1 of the Supplementary Material. 
Reasonable performance without recalibration was found by the model for 
cohorts A and B, demonstrated by the loess smoother which was relatively close 
to the identity line. The model generally underestimated the risk of Grade ≥2 275 
AET. Increasingly poor calibration was observed for cohorts C, D and E. 
Calibration plots generated after recalibration are shown in Figure 2, and the 
values for the calibration-in-the-large and calibration slope are listed in Table 2. 
For cohorts A and B, good calibration was achieved after recalibration. 
Similarly, for cohort C recalibration moderately improved the agreement 280 
between predicted and observed risk. For cohorts D and E, calibration did not 
improve after recalibration, indicated by the limited range of predicted 
probabilities (see Figure 2). 
  




Recently, we established a multivariable NTCP model for AET in LA-NSCLC 
undergoing IMRT or VMAT and after thorough internal validation the model 
proved to be robust [20]. However, it is of paramount importance to perform 
external validation in order to ensure that the model is transportable to other 290 
patient cohorts [21, 23]. This means that the model produces accurate 
predictions in a sample that was drawn from a different but plausibly related 
population. Several components of ‘transportability’ can be distinguished, such 
as historical (e.g., a different time period), geographical (e.g., treated in a 
different hospital) and methodological (e.g., differences in toxicity scoring) 295 
transportability [41]. To account for all these components of transportability, we 
externally validated our previously established NTCP model for Grade ≥2 AET 
in cohorts of (LA-)NSCLC patients that were treated by (chemo-)radiotherapy in 
different hospitals (cohort B-E), receiving different radiation fractionation 
schedules (cohort C-E) and in a historically different period of time with less 300 
conformal dose delivery techniques (cohort C). Ideally, an NTCP model 
performs well in every patient cohort external to the cohort the model was 
developed on. However, this so-called ‘strong calibration’ is only considered 
possible in utopia [35]. Therefore, applying an established NTCP model in 
different patient cohorts often needs some form of adjustments to account for 305 
local circumstances [42, 43]. 
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Recalibration is a controlled form of model updating; i.e., the coefficients of the 
model are adjusted to correct for differences in for instance event rates. Initial 
calibration of the model in cohort A and B was moderate (see Figure S1 in the 
Supplementary Material). Underestimation of Grade ≥2 AET was seen, which is 310 
possibly due to a lower incidence of Grade ≥2 AET in the training cohort 
(35.6%) compared to cohort A (70.2%) and cohort B (49.3%). The class 
imbalance in the training cohort can affect the estimate of the model intercept 
and skews the predicted probabilities. After recalibration of the NTCP model for 
cohort A and B, calibration improved (see Figure 2). Discrimination of the 315 
model was good for the patients in cohort A and B (AUC 0.89 and 0.81, 
respectively). Formerly, we hypothesized that differences in dose delivery 
techniques influenced NTCP modelling since the models based on 3D-CRT did 
not perform well in head and neck cancer patients who underwent IMRT [18, 
20, 44, 45]. Although cohort C differs substantially from the training cohort 320 
regarding treatment technique (3D-CRT vs IMRT/VMAT), radiation dose (49.5-
94.5 Gy vs 66 Gy), the application of concurrent chemotherapy, and the time 
period (1998-2003 vs 2008-2010), the current model performed surprisingly 
well for this population (AUC 0.84 with a moderately good recalibration curve). 
Cohorts D and E showed poor discrimination (AUC 0.64 and 0.63 respectively) 325 
and (re)calibration (see Figure 1 and Supplementary Material Figure S1). Re-
estimating the regression coefficients or adding additional predictors that are 
known for their association with AET (for example, overall treatment time 
17 
 
(OTT) and chemotherapy regimen; see below) are approaches to improve model 
predictions. Besides this, there may be several other reasons for the poor model 330 
performance in these cohorts. Firstly, the NTCP model was developed using the 
RTOG grading scale for AET. However, toxicity for the patients in cohort D and 
E was scored using the CTCAE grading scales for AET. Differences between 
scoring systems were reported to be of importance in modelling of toxicity, for 
instance for modelling the risk of radiation-induced pneumonitis [46]. It is likely 335 
that such differences in grading scales affect AET modelling as well. This was 
illustrated for the patients of cohort B for whom both the RTOG and CTCAE 
v4.0 grading of AET were available. Applying the NTCP model using the 
CTCAE-based AET scores resulted in a high discrimination with AUC of 0.80 
(compared to 0.81 for the RTOG based scores), however, model calibration was 340 
poor since it considerably underestimated the risk of CTCAE Grade ≥2 AET 
(data not shown). The latter can be explained by the finding that in 35.6% of the 
patients AET was scored as Grade 1 using the RTOG scale and as Grade 2 using 
the CTCAE scale (see Table S2 in the Supplementary Material). Secondly, the 
patients from cohort D received concurrent chemoradiotherapy in a 345 
fundamentally different protocol compared to the patients in the training cohort 
as they received daily low-dose cisplatin and moderately hypofractionated 
radiotherapy schedules. Thirdly, the OTT is shorter for cohort D and E (5 
weeks) than for the training cohort (6.5 weeks). Besides, the majority of patients 
(88.5%) from cohort E were treated twice-daily. Both factors are known to result 350 
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in a strong increase of AET [3, 6]; including OTT in the NTCP model for 
patients receiving treatment with a shorter OTT is likely to improve model 
performance for these cohorts as reported by Dehing-Oberije et al. [3]. 
Despite our aim to thoroughly validate the established NTCP model for Grade 
≥2 AET by assessing the transportability of the model using multiple different 355 
patient cohorts, some potential limitations should be noted. Firstly, the data of 
most cohorts were retrieved retrospectively (except cohort D and E) possibly 
introducing unwanted bias. Furthermore, for some patients of the validation 
cohorts the necessary NTCP model predictor values could not be retrieved 
resulting in exclusion of these patients. The number of patients of the separate 360 
cohorts may be considered low for model validation, however, the total number 
of patients (n=603) included in the validation cohorts is substantial. For future 
work, by making data ‘smarter’, e.g., by implementing semantic technologies 
[47, 48], and more easily accessible, by adhering to the FAIR data principles 
[49], distributed learning techniques can allow training and validation of models  365 
in much larger cohorts of patients that were not treated according to any specific 
study protocol [50]. Finally, this study is an external validation of a model 
previously published by us and we therefore encourage independent external 
validation by other research groups.  
In conclusion, the established NTCP model for the prediction of Grade ≥2 AET 370 
in patients treated for locally advanced NSCLC successfully validated in 3 out 
of 5 patient cohorts, but performed poor in 2 cohorts that were significantly 
19 
 
different for many variables. Before implementing the NTCP model in clinical 
practice, one should always check model discrimination and calibration 
performance in a local cohort representative of the patients for which the model 375 
is intended to be used in the future. If good discrimination but poor calibration is 
observed a local recalibration of the model is advised. After implementation the 
model should be evaluated over time for new patients since treatments and 
cohorts change and model performance can deteriorate to the point where the 
model coefficients need to be updated or additional predictors may become 380 
relevant and complete remodelling is necessary. 
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Table 1. Comparison of validation cohort characteristics with the training cohort for the NTCP model predictors and AET. 
                                




A B C D E A-E† 
n=149   n=47 p n=73 p n=129 p n=172 p n=182 p n=603 p 
Gender (%) 
              
 















Female 52 (34.9) 
 
29 (61.7) 0.002 35 (47.9) 0.08 41 (31.8) 0.61 70 (40.7) 0.30 69 (37.9) 0.65 244 (40.5) 0.65 
T-stage (%) 
              
 















≥3 74 (49.7) 
 
26 (55.3) 0.51 49 (67.1) 0.02 67 (51.9) 0.72 81 (47.1) 0.66 104 (57.1) 0.19 327 (54.2) 0.19 
Chemotherapy (%) 
              
 















Sequential/none 46/10 (37.6) 
 
12/2 (29.8) 0.38 24/4 (38.4) 1.00 31/73 (80.6) <0.001 - <0.001 24/2 (14.3) <0.001 91/81 (28.5) <0.001 






















































Grade ≥2 AET 
              
 
RTOG 53 (35.6) 
 










62 (84.9) <0.001 - 
 
102 (59.3) <0.001 124 (68.1) <0.001 - 
 
Grade ≥3 AET 
              
 
RTOG 13 (8.7) 
 




124 (20.6) <0.001 
  CTCAE* -   -   13 (17.8) 0.07 -   40 (23.3) <0.001 55 (30.2) <0.001 -   
 535 
 
Abbreviations: NTCP = normal-tissue complication probability; AET = acute esophageal toxicity; Dmean = mean dose; IQR = interquartile range; EQD210 = equivalent dose in 2 Gy fractions with α/β = 10 Gy; 
RTOG = Radiation Therapy Oncology Group; CTCAE = Common Toxicity Criteria Adverse Effects; N/A = not applicable. 
The p-values are calculated for the comparison between the validation cohort and the training cohort (Mann-Whitney-U or Fisher’s exact test where appropriate). Bold p-values are statistically significant. 
*p-values of AET scoring using CTCAE are calculated with respect to the training cohort AET scoring that used RTOG. 




Table 2. Performance of the NTCP model after recalibration for the different patient cohorts. 






   
A B C D E A-E 
  n=149   n=47 n=73 n=129 n=172 n=182 n=603 
Pseudo R²s 












 0.55  0.38  0.36  0.08  0.06  0.24 
Discrimination 
         
 
AUC (95% CI) 
 
 0.84 (0.77-0.91) 
 












 0.45  0.30  0.25  0.06  0.05  0.19 
Calibration 






 1.18  0.20 -0.15 -0.22  1.63  0.57 
  Calibration slope    1.00    1.36  0.71  0.60  0.40  0.29  0.50 





Figure 1. ROC curves of the previously published NTCP model [20] applied on 540 
all patient cohorts showing good discriminating performance for 3 out of 5 
validation cohorts as indicated by AUC values (>0.80). 
Abbreviations: ROC = receiver operating characteristic; NTCP = normal-tissue 
complication probability; AUC = area under the curve. 
 545 
Figure 2. Calibration plots of the NTCP model applied on all validation cohorts 
separate and combined, after recalibration per cohort. Recalibrated predicted 
probabilities are calculated by inserting the cohort-specific calibration-in-the-
large and calibration slope values in Formulas 3 and 4. The triangles indicate 
grouped predicted probabilities of Grade ≥2 AET vs grouped observed 550 
frequencies. The vertical lines represent 95% confidence intervals. A loess 
smoother was fitted and displayed by the black line. Perfect predictions should 
be close to the dashed 45° reference line. Double histograms of patients with and 
without Grade ≥2 AET, binned according to their predicted probabilities, are 
displayed at the bottom. 555 
Abbreviations: NTCP = normal-tissue complication probability; AET = acute 




Figure 1. Receiver operating characteristic curves for the NTCP model on all 
































Table S1. Patient, tumor and treatment characteristics for the training and validation cohorts. 
    Training cohort   Validation cohorts 
Characteristics   
A B C D E A-E 
n=149   n=47 p n=73 p n=129 p n=172 p n=182 p n=603 p 
Age (y) (range) 





Median 63 (36-78) 
 
65 (46-82) 0.35 68 (45-85) 0.003 70 (31-88) <0.001 63 (38-85) 0.33 64 (38-87) 0.08 66 (31-88) 0.002 
Performance (%) 
              
 
































- 0.73 - 0.17 44 (34.1) <0.001 - <0.001 1 (0.5) <0.001 45 (7.5) <0.001 
Tumor cell type (%) 
              
 













































Other/Missing 6/6 (4.0/4.0) 
 
5/0 (10.6/-) 0.02 3/2 (4.1/2.7) 0.50 
N/A/129 
(-/100.0) 




Clinical Stage (%) 















































































- 0.21 - 0.04 - <0.001 10 (5.8) <0.001 - 0.002 10 (1.7) <0.001 
N-stage (%) 
              
 






























3 37 (24.8) 
 
16 (34.0) 0.15 22 (30.1) 0.68 6 (4.7) <0.001 21 (12.2) <0.001 55 (30.2) 0.26 120 (19.9) 0.002 
Radiation dose (%) 
              
 











































































- 0.36 - <0.001 42 (32.6) <0.001 - 0.05 - <0.001 42 (7.0) <0.001 
Technique (%) 



















































- <0.001 - <0.001 - <0.001 - <0.001 75 (41.2) <0.001 75 (12.4) <0.001 
PTV volume (cm3) 





Median (IQR) 480 (358-629) 
  







Abbreviations: KS = Karnofsky performance score; WHO = World Health Organization performance score; SCC = squamous cell carcinoma; AC = adenocarcinoma; NSCLC = non-small cell lung cancer; IMRT = 
intensity-modulated radiation therapy; VMAT = volumetric-modulated arc therapy; 3D-CRT = 3-dimensional conformal radiotherapy; PTV = planning target volume; IQR = interquartile range; N/A = not 
available. Bold p-values are statistically significant. 





Table S2. Comparison of RTOG and CTCAE scoring criteria for acute esophageal toxicity (esophagitis and dysphagia). 
System 
Organ tissue/ 
system organ class 
Adverse event 
Grade 







Mild dysphagia or 
odynophagia; may require 
topical anesthetic or non-
narcotic analgesics; may 
require soft diet 
Moderate dysphagia or 
odynophagia; may 
require narcotic 
analgesics; may require 
puree or liquid diet 
Severe dysphagia or odynophagia 
with dehydration or weight loss 
>15% from pretreatment baseline) 








Gastrointestinal Dysphagia Symptomatic, able to eat 
regular diet 
Symptomatic and altered 
eating/swallowing (e.g., 
altered dietary habits, 
oral supplements); IV 
fluids indicated <24 hrs 
Symptomatic and severely altered 
eating/swallowing (e.g., 
inadequate oral caloric or fluid 
intake); IV fluids, tube feedings, or 







Gastrointestinal Esophagitis Asymptomatic pathologic, 
radiographic, or 
endoscopic findings only 
Symptomatic; altered 
eating/swallowing (e.g., 
altered dietary habits, 
oral supplements); IV 
fluids indicated <24 hrs 
Symptomatic and severely altered 
eating/swallowing (e.g., 
inadequate oral caloric or fluid 
intake); IV fluids, tube feedings, or 






Gastrointestinal Dysphagia Symptomatic, able to eat 
regular diet 
Symptomatic and altered 
eating/swallowing 
Severely altered eating/swallowing; 







Gastrointestinal Esophagitis Asymptomatic; clinical or 
diagnostic observations 





Severely altered eating/swallowing; 






 Abbreviations: RTOG = Radiation Therapy Oncology Group; CTCAE = Common Toxicity Criteria Adverse Effects; NG = nasogastric; IV = intravenous; TPN = total parenteral nutrition. RTOG organ tissues are listed under 





Figure S1. Calibration plots of the NTCP model applied on all validation 
cohorts separate and combined, without recalibration (calibration-in-the-large 
and calibration slope are given but not applied). The triangles indicate grouped 
predicted probabilities of Grade ≥2 AET vs grouped observed frequencies. The 
vertical lines represent 95% confidence intervals. A loess smoother is fitted and 
displayed by the black line. Perfect predictions should be close to the dashed 45° 
reference line. Double histograms of patients with and without Grade ≥2 AET, 
binned according to their predicted probabilities, are displayed at the bottom. 
Abbreviations: NTCP = normal-tissue complication probability; AUC = area 
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